MediGene signs up Triton Pharma to commercialise Veregen in Canada
This article was originally published in Scrip
Executive Summary
Triton Pharma, a Canadian company focused on commercialising drugs in women's health, urology and dermatology, has secured an exclusive license and supply agreement from MediGene covering the commercialisation of Veregen ointment to treat genital warts in Canada. Triton takes on responsibility for drug approval i Canada and will pay MediGene up to €2.1 million in milestones plus a double digit royalty on subsequent sales.